Search

Your search keyword '"Sparks, Jeffrey A."' showing total 1,165 results
Start Over Author "Sparks, Jeffrey A."
1,165 results on '"Sparks, Jeffrey A."'

3. Forced vital capacity trajectories and risk of lung transplant and ILD-related mortality among patients with rheumatoid arthritis-associated interstitial lung disease

Author

Venkat, Rathnam K., Hayashi, Keigo, Juge, Pierre-Antoine, McDermott, Gregory, Paudel, Misti, Wang, Xiaosong, Vanni, Kathleen M. M., Kowalski, Emily N., Qian, Grace, Bade, Katarina J., Saavedra, Alene A., Mueller, Kevin T., Chang, Sung Hae, Dellaripa, Paul F., Weinblatt, Michael E., Shadick, Nancy A., Doyle, Tracy J., Dieude, Philippe, and Sparks, Jeffrey A.

Published
2024
Full Text
View/download PDF

4. Screening, diagnosis, and monitoring of interstitial lung disease in autoimmune rheumatic diseases: A narrative review.

Author

Good, Samuel, Sparks, Jeffrey, and Volkmann, Elizabeth

Subjects
Inflammatory myositis, Interstitial lung disease, Primary Sjogren’s syndrome, Rheumatoid arthritis, Systemic lupus erythematosus, Systemic sclerosis
Abstract

Interstitial lung disease (ILD) is a common and serious manifestation of autoimmune rheumatic diseases. While the prevalence of ILD differs among the individual autoimmune rheumatic diseases, ILD remains an important cause of morbidity and mortality in systemic sclerosis, systemic lupus erythematosus, mixed connective tissue disease, primary Sjögrens disease, rheumatoid arthritis, and idiopathic inflammatory myositis. The present review summarizes recent literature on autoimmune-associated ILD with a focus on screening and monitoring for ILD progression. Reflecting on the currently available evidence, the authors propose a guideline for monitoring for progression in patients with newly diagnosed autoimmune-associated ILD. This review also highlights clinical and biological predictors of progressive pulmonary fibrosis and describes opportunity for further study in the rapidly evolving area of rheumatology and pulmonology.

Published
2024

8. Obstetric outcomes in women with rheumatic disease and COVID-19 in the context of vaccination status.

Author

Maguire, Sinead, Al-Emadi, Samar, Alba, Paula, Aguiar, Mathia, Al Lawati, Talal, Alle, Gelsomina, Bermas, Bonnie, Bhana, Suleman, Branimir, Anic, Bulina, Inita, Clowse, Megan, Cogo, Karina, Colunga, Iris, Cook, Claire, Cortez, Karen, Dao, Kathryn, Gianfrancesco, Milena, Gore-Massey, Monique, Gossec, Laure, Grainger, Rebecca, Hausman, Jonathon, Hsu, Tiffany, Hyrich, Kimme, Isnardi, Carolina, Kawano, Yumeko, Kilding, Rachael, Kusevich, Daria, Lawson-Tovey, Saskia, Liew, Jean, McCarthy, Eoghan, Montgumery, Anna, Moyano, Sebastian, Nasir, Noreen, Padjen, Ivan, Papagoras, Charalampos, Patel, Naomi, Pera, Mariana, Pisoni, Cecilia, Pons-Estel, Guillermo, Quiambao, Antonio, Quintana, Rosana, Ruderman, Eric, Sattui, Sebastian, Savio, Veronica, Sciascia, Savino, Sencarova, Marieta, Morales, Rosa, Siddique, Faizah, Sirotich, Emily, Sparks, Jeffrey, Strangfeld, Anja, Sufka, Paul, Tanner, Helen, Tissera, Yohana, Wallace, Zachary, Werner, Marina, Wise, Leanna, Worthing, Angus, Zell, JoAnn, Zepa, Julija, Machado, Pedro, Yazdany, Jinoos, Robinson, Philip, and Conway, Richard

Subjects
COVID-19, patient outcomes, pregnancy, rheumatic disease, vaccination, women’s health, Pregnancy, Infant, Newborn, Female, Humans, COVID-19 Vaccines, COVID-19, COVID-19 Testing, Rheumatic Diseases, Premature Birth, Vaccination
Abstract

OBJECTIVE: To describe obstetric outcomes based on COVID-19 vaccination status, in women with rheumatic and musculoskeletal diseases (RMDs) who developed COVID-19 during pregnancy. METHODS: Data regarding pregnant women entered into the COVID-19 Global Rheumatology Alliance registry from 24 March 2020-25 February 2022 were analysed. Obstetric outcomes were stratified by number of COVID-19 vaccine doses received prior to COVID-19 infection in pregnancy. Descriptive differences between groups were tested using the chi-squared or Fishers exact test. RESULTS: There were 73 pregnancies in 73 women with RMD and COVID-19. Overall, 24.7% (18) of pregnancies were ongoing, while of the 55 completed pregnancies, 90.9% (50) of pregnancies resulted in livebirths. At the time of COVID-19 diagnosis, 60.3% (n = 44) of women were unvaccinated, 4.1% (n = 3) had received one vaccine dose while 35.6% (n = 26) had two or more doses. Although 83.6% (n = 61) of women required no treatment for COVID-19, 20.5% (n = 15) required hospital admission. COVID-19 resulted in delivery in 6.8% (n = 3) of unvaccinated women and 3.8% (n = 1) of fully vaccinated women. There was a greater number of preterm births (PTB) in unvaccinated women compared with fully vaccinated 29.5% (n = 13) vs 18.2% (n = 2). CONCLUSIONS: In this descriptive study, unvaccinated pregnant women with RMD and COVID-19 had a greater number of PTB compared with those fully vaccinated against COVID-19. Additionally, the need for COVID-19 pharmacological treatment was uncommon in pregnant women with RMD regardless of vaccination status. These results support active promotion of COVID-19 vaccination in women with RMD who are pregnant or planning a pregnancy.

Published
2023

9. 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases

Author

Bass, Anne R, Chakravarty, Eliza, Akl, Elie A, Bingham, Clifton O, Calabrese, Leonard, Cappelli, Laura C, Johnson, Sindhu R, Imundo, Lisa F, Winthrop, Kevin L, Arasaratnam, Reuben J, Baden, Lindsey R, Berard, Roberta, Bridges, S Louis, Cheah, Jonathan TL, Curtis, Jeffrey R, Ferguson, Polly J, Hakkarinen, Ida, Onel, Karen B, Schultz, Grayson, Sivaraman, Vidya, Smith, Benjamin J, Sparks, Jeffrey A, Vogel, Tiphanie P, Williams, Eleanor Anderson, Calabrese, Cassandra, Cunha, Joanne S, Fontanarosa, Joann, Gillispie‐Taylor, Miriah C, Gkrouzman, Elena, Iyer, Priyanka, Lakin, Kimberly S, Legge, Alexandra, Lo, Mindy S, Lockwood, Megan M, Sadun, Rebecca E, Singh, Namrata, Sullivan, Nancy, Tam, Herman, Turgunbaev, Marat, Turner, Amy S, and Reston, James

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Autoimmune Disease, Immunization, Prevention, Vaccine Related, 3.4 Vaccines, Prevention of disease and conditions, and promotion of well-being, Good Health and Well Being, Child, Humans, United States, Rheumatology, Antirheumatic Agents, Musculoskeletal Diseases, Vaccination
Abstract

ObjectiveTo provide evidence-based recommendations on the use of vaccinations in children and adults with rheumatic and musculoskeletal diseases (RMDs).MethodsThis guideline follows American College of Rheumatology (ACR) policy guiding management of conflicts of interest and disclosures and the ACR guideline development process, which includes the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology. It also adheres to the Appraisal of Guidelines for Research and Evaluation (AGREE) criteria. A core leadership team consisting of adult and pediatric rheumatologists and a guideline methodologist drafted clinical population, intervention, comparator, outcomes (PICO) questions. A review team performed a systematic literature review for the PICO questions, graded the quality of evidence, and produced an evidence report. An expert Voting Panel reviewed the evidence and formulated recommendations. The panel included adult and pediatric rheumatology providers, infectious diseases specialists, and patient representatives. Consensus required ≥70% agreement on both the direction and strength of each recommendation.ResultsThis guideline includes expanded indications for some vaccines in patients with RMDs, as well as guidance on whether to hold immunosuppressive medications or delay vaccination to maximize vaccine immunogenicity and efficacy. Safe approaches to the use of live attenuated vaccines in patients taking immunosuppressive medications are also addressed. Most recommendations are conditional and had low quality of supporting evidence.ConclusionApplication of these recommendations should consider patients' individual risk for vaccine-preventable illness and for disease flares, particularly if immunosuppressive medications are held for vaccination. Shared decision-making with patients is encouraged in clinical settings.

Published
2023

12. Characteristics and Outcomes of People With Gout Hospitalized Due to COVID‐19: Data From the COVID‐19 Global Rheumatology Alliance Physician‐Reported Registry

Author

Jatuworapruk, Kanon, Montgomery, Anna, Gianfrancesco, Milena, Conway, Richard, Durcan, Laura, Graef, Elizabeth R, Jayatilleke, Aruni, Keen, Helen, Kilian, Adam, Young, Kristen, Carmona, Loreto, Cogo, Adriana Karina, Duarte‐García, Alí, Gossec, Laure, Hasseli, Rebecca, Hyrich, Kimme L, Langlois, Vincent, Lawson‐Tovey, Saskia, Malcata, Armando, Mateus, Elsa F, Schafer, Martin, Scirè, Carlo Alberto, Sigurdardottir, Valgerdur, Sparks, Jeffrey A, Strangfeld, Anja, Xavier, Ricardo M, Bhana, Suleman, Gore‐Massy, Monique, Hausmann, Jonathan, Liew, Jean W, Sirotich, Emily, Sufka, Paul, Wallace, Zach, Machado, Pedro M, Yazdany, Jinoos, Grainger, Rebecca, and Robinson, Philip C

Subjects
Prevention, Clinical Research, Good Health and Well Being
Abstract

ObjectiveTo describe people with gout who were diagnosed with coronavirus disease 2019 (COVID-19) and hospitalized and to characterize their outcomes.MethodsData on patients with gout hospitalized for COVID-19 between March 12, 2020, and October 25, 2021, were extracted from the COVID-19 Global Rheumatology Alliance registry. Descriptive statistics were used to describe the demographics, comorbidities, medication exposures, and COVID-19 outcomes including oxygenation or ventilation support and death.ResultsOne hundred sixty-three patients with gout who developed COVID-19 and were hospitalized were included. The mean age was 63 years, and 85% were male. The majority of the group lived in the Western Pacific Region (35%) and North America (18%). Nearly half (46%) had two or more comorbidities, with hypertension (56%), cardiovascular disease (28%), diabetes mellitus (26%), chronic kidney disease (25%), and obesity (23%) being the most common. Glucocorticoids and colchicine were used pre-COVID-19 in 11% and 12% of the cohort, respectively. Over two thirds (68%) of the cohort required supplemental oxygen or ventilatory support during hospitalization. COVID-19-related death was reported in 16% of the overall cohort, with 73% of deaths documented in people with two or more comorbidities.ConclusionThis cohort of people with gout and COVID-19 who were hospitalized had high frequencies of ventilatory support and death. This suggests that patients with gout who were hospitalized for COVID-19 may be at risk of poor outcomes, perhaps related to known risk factors for poor outcomes, such as age and presence of comorbidity.

Published
2022

14. Development of a Prediction Model for COVID‐19 Acute Respiratory Distress Syndrome in Patients With Rheumatic Diseases: Results From the Global Rheumatology Alliance Registry

Author

Izadi, Zara, Gianfrancesco, Milena A, Aguirre, Alfredo, Strangfeld, Anja, Mateus, Elsa F, Hyrich, Kimme L, Gossec, Laure, Carmona, Loreto, Lawson‐Tovey, Saskia, Kearsley‐Fleet, Lianne, Schaefer, Martin, Seet, Andrea M, Schmajuk, Gabriela, Jacobsohn, Lindsay, Katz, Patricia, Rush, Stephanie, Al‐Emadi, Samar, Sparks, Jeffrey A, Hsu, Tiffany Y‐T, Patel, Naomi J, Wise, Leanna, Gilbert, Emily, Duarte‐García, Alí, Valenzuela‐Almada, Maria O, Ugarte‐Gil, Manuel F, Ribeiro, Sandra Lúcia Euzébio, de Oliveira Marinho, Adriana, de Azevedo Valadares, Lilian David, Di Giuseppe, Daniela, Hasseli, Rebecca, Richter, Jutta G, Pfeil, Alexander, Schmeiser, Tim, Isnardi, Carolina A, Torres, Alvaro A Reyes, Alle, Gelsomina, Saurit, Verónica, Zanetti, Anna, Carrara, Greta, Labreuche, Julien, Barnetche, Thomas, Herasse, Muriel, Plassart, Samira, Santos, Maria José, Rodrigues, Ana Maria, Robinson, Philip C, Machado, Pedro M, Sirotich, Emily, Liew, Jean W, Hausmann, Jonathan S, Sufka, Paul, Grainger, Rebecca, Bhana, Suleman, Costello, Wendy, Wallace, Zachary S, Yazdany, Jinoos, and Registry, Global Rheumatology Alliance

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Machine Learning and Artificial Intelligence, Emerging Infectious Diseases, Acute Respiratory Distress Syndrome, Rare Diseases, Coronaviruses, Prevention, Lung, Women's Health, Infectious Diseases, Good Health and Well Being, Global Rheumatology Alliance Registry, Clinical sciences
Abstract

ObjectiveSome patients with rheumatic diseases might be at higher risk for coronavirus disease 2019 (COVID-19) acute respiratory distress syndrome (ARDS). We aimed to develop a prediction model for COVID-19 ARDS in this population and to create a simple risk score calculator for use in clinical settings.MethodsData were derived from the COVID-19 Global Rheumatology Alliance Registry from March 24, 2020, to May 12, 2021. Seven machine learning classifiers were trained on ARDS outcomes using 83 variables obtained at COVID-19 diagnosis. Predictive performance was assessed in a US test set and was validated in patients from four countries with independent registries using area under the curve (AUC), accuracy, sensitivity, and specificity. A simple risk score calculator was developed using a regression model incorporating the most influential predictors from the best performing classifier.ResultsThe study included 8633 patients from 74 countries, of whom 523 (6%) had ARDS. Gradient boosting had the highest mean AUC (0.78; 95% confidence interval [CI]: 0.67-0.88) and was considered the top performing classifier. Ten predictors were identified as key risk factors and were included in a regression model. The regression model that predicted ARDS with 71% (95% CI: 61%-83%) sensitivity in the test set, and with sensitivities ranging from 61% to 80% in countries with independent registries, was used to develop the risk score calculator.ConclusionWe were able to predict ARDS with good sensitivity using information readily available at COVID-19 diagnosis. The proposed risk score calculator has the potential to guide risk stratification for treatments, such as monoclonal antibodies, that have potential to reduce COVID-19 disease progression.

Published
2022

15. Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study

Author

Izadi, Zara, Gianfrancesco, Milena A, Schmajuk, Gabriela, Jacobsohn, Lindsay, Katz, Patricia, Rush, Stephanie, Ja, Clairissa, Taylor, Tiffany, Shidara, Kie, Danila, Maria I, Wysham, Katherine D, Strangfeld, Anja, Mateus, Elsa F, Hyrich, Kimme L, Gossec, Laure, Carmona, Loreto, Lawson-Tovey, Saskia, Kearsley-Fleet, Lianne, Schaefer, Martin, Al-Emadi, Samar, Sparks, Jeffrey A, Hsu, Tiffany Y-T, Patel, Naomi J, Wise, Leanna, Gilbert, Emily, Duarte-García, Alí, Valenzuela-Almada, Maria O, Ugarte-Gil, Manuel F, Ljung, Lotta, Scirè, Carlo A, Carrara, Greta, Hachulla, Eric, Richez, Christophe, Cacoub, Patrice, Thomas, Thierry, Santos, Maria J, Bernardes, Miguel, Hasseli, Rebecca, Regierer, Anne, Schulze-Koops, Hendrik, Müller-Ladner, Ulf, Pons-Estel, Guillermo, Tanten, Romina, Nieto, Romina E, Pisoni, Cecilia N, Tissera, Yohana S, Xavier, Ricardo, Marques, Claudia D Lopes, Pileggi, Gecilmara CS, Robinson, Philip C, Machado, Pedro M, Sirotich, Emily, Liew, Jean W, Hausmann, Jonathan S, Sufka, Paul, Grainger, Rebecca, Bhana, Suleman, Gore-Massy, Monique, Wallace, Zachary S, Yazdany, Jinoos, Registry, COVID-19 Global Rheumatology Alliance, Dahou, Brahim, Gómez, Gimena, Roberts, Karen, Baez, Roberto M, Coello, Vanessa V Castro, Salinas, María J Haye, Maldonado, Federico N, Reyes, Alvaro A, Alle, Gelsomina, Ficco, Hernán Maldonado, Nieto, Romina, Gobbi, Carla, Tissera, Yohana, Pisoni, Cecilia, Paula, Alba, Albiero, Juan A, Schmid, Maria M, Cosatti, Micaela, Gamba, Maria J, Leandro, Carlevaris, Cusa, María A, German, Noelia, Bellomio, Veronica, Takashima, Lorena, Pera, Mariana, Cogo, Karina, Elkin, Maria S Gálvez, Medina, María A, Savio, Veronica, Tessel, Romina Rojas, Alamino, Rodolfo P, Werner, Marina L, Ornella, Sofía, Casalla, Luciana, de la Vega, Maria, Severina, María, García, Mercedes, and Lucero, Luciana Gonzalez

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Coronaviruses, Women's Health, Emerging Infectious Diseases, Social Determinants of Health, Infectious Diseases, Good Health and Well Being, COVID-19 Global Rheumatology Alliance Registry, Clinical sciences
Abstract

BackgroundDifferences in the distribution of individual-level clinical risk factors across regions do not fully explain the observed global disparities in COVID-19 outcomes. We aimed to investigate the associations between environmental and societal factors and country-level variations in mortality attributed to COVID-19 among people with rheumatic disease globally.MethodsIn this observational study, we derived individual-level data on adults (aged 18-99 years) with rheumatic disease and a confirmed status of their highest COVID-19 severity level from the COVID-19 Global Rheumatology Alliance (GRA) registry, collected between March 12, 2020, and Aug 27, 2021. Environmental and societal factors were obtained from publicly available sources. The primary endpoint was mortality attributed to COVID-19. We used a multivariable logistic regression to evaluate independent associations between environmental and societal factors and death, after controlling for individual-level risk factors. We used a series of nested mixed-effects models to establish whether environmental and societal factors sufficiently explained country-level variations in death.Findings14 044 patients from 23 countries were included in the analyses. 10 178 (72·5%) individuals were female and 3866 (27·5%) were male, with a mean age of 54·4 years (SD 15·6). Air pollution (odds ratio 1·10 per 10 μg/m3 [95% CI 1·01-1·17]; p=0·0105), proportion of the population aged 65 years or older (1·19 per 1% increase [1·10-1·30]; p

Published
2022

17. Earlier vs. later time period of COVID-19 infection and emergent autoimmune signs, symptoms, and serologies

Author

Oakes, Emily G., Dillon, Eilish, Buhler, Katherine A., Guan, Hongshu, Paudel, Misti, Marks, Kathryne, Adejoorin, Ifeoluwakiisi, Yee, Jeong, Ellrodt, Jack, Tedeschi, Sara, Sparks, Jeffrey, Case, Siobhan M., Hsu, Tiffany, Solomon, Daniel H., Jonsson, A. Helena, Alexander, Roberta Vezza, Rao, Deepak A., Choi, May Y., and Costenbader, Karen H.

Published
2024
Full Text
View/download PDF

18. Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance

Author

Ugarte-Gil, Manuel Francisco, Alarcón, Graciela S, Izadi, Zara, Duarte-García, Ali, Reátegui-Sokolova, Cristina, Clarke, Ann Elaine, Wise, Leanna, Pons-Estel, Guillermo J, Santos, Maria Jose, Bernatsky, Sasha, Ribeiro, Sandra Lúcia Euzébio, Al Emadi, Samar, Sparks, Jeffrey A, Hsu, Tiffany Y-T, Patel, Naomi J, Gilbert, Emily L, Valenzuela-Almada, Maria O, Jönsen, Andreas, Landolfi, Gianpiero, Fredi, Micaela, Goulenok, Tiphaine, Devaux, Mathilde, Mariette, Xavier, Queyrel, Viviane, Romão, Vasco C, Sequeira, Graca, Hasseli, Rebecca, Hoyer, Bimba, Voll, Reinhard E, Specker, Christof, Baez, Roberto, Castro-Coello, Vanessa, Ficco, Hernan Maldonado, Neto, Edgard Torres Reis, Ferreira, Gilda Aparecida Aparecida, Monticielo, Odirlei Andre André, Sirotich, Emily, Liew, Jean, Hausmann, Jonathan, Sufka, Paul, Grainger, Rebecca, Bhana, Suleman, Costello, Wendy, Wallace, Zachary S, Jacobsohn, Lindsay, Taylor, Tiffany, Ja, Clairissa, Strangfeld, Anja, Mateus, Elsa F, Hyrich, Kimme L, Carmona, Loreto, Lawson-Tovey, Saskia, Kearsley-Fleet, Lianne, Schäfer, Martin, Machado, Pedro M, Robinson, Philip C, Gianfrancesco, Milena, and Yazdany, Jinoos

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Lupus, Emerging Infectious Diseases, Women's Health, Infectious Diseases, Minority Health, Autoimmune Disease, Coronaviruses, 6.1 Pharmaceuticals, Inflammatory and immune system, Good Health and Well Being, COVID-19, Humans, Lupus Erythematosus, Systemic, Male, Prednisone, Rheumatology, Severity of Illness Index, lupus erythematosus, systemic, epidemiology, Immunology, Public Health and Health Services, Arthritis & Rheumatology, Clinical sciences
Abstract

AimTo determine characteristics associated with more severe outcomes in a global registry of people with systemic lupus erythematosus (SLE) and COVID-19.MethodsPeople with SLE and COVID-19 reported in the COVID-19 Global Rheumatology Alliance registry from March 2020 to June 2021 were included. The ordinal outcome was defined as: (1) not hospitalised, (2) hospitalised with no oxygenation, (3) hospitalised with any ventilation or oxygenation and (4) death. A multivariable ordinal logistic regression model was constructed to assess the relationship between COVID-19 severity and demographic characteristics, comorbidities, medications and disease activity.ResultsA total of 1606 people with SLE were included. In the multivariable model, older age (OR 1.03, 95% CI 1.02 to 1.04), male sex (1.50, 1.01 to 2.23), prednisone dose (1-5 mg/day 1.86, 1.20 to 2.66, 6-9 mg/day 2.47, 1.24 to 4.86 and ≥10 mg/day 1.95, 1.27 to 2.99), no current treatment (1.80, 1.17 to 2.75), comorbidities (eg, kidney disease 3.51, 2.42 to 5.09, cardiovascular disease/hypertension 1.69, 1.25 to 2.29) and moderate or high SLE disease activity (vs remission; 1.61, 1.02 to 2.54 and 3.94, 2.11 to 7.34, respectively) were associated with more severe outcomes. In age-adjusted and sex-adjusted models, mycophenolate, rituximab and cyclophosphamide were associated with worse outcomes compared with hydroxychloroquine; outcomes were more favourable with methotrexate and belimumab.ConclusionsMore severe COVID-19 outcomes in individuals with SLE are largely driven by demographic factors, comorbidities and untreated or active SLE. Patients using glucocorticoids also experienced more severe outcomes.

Published
2022

23. Rapid Adoption of Telemedicine in Rheumatology Care During the COVID‐19 Pandemic Highlights Training and Supervision Concerns Among Rheumatology Trainees

Author

Yeoh, Su‐Ann, Young, Kristen, Putman, Michael, Sattui, Sebastian, Conway, Richard, Graef, Elizabeth, Kilian, Adam, Konig, Maximilian, Sparks, Jeffrey, Ugarte‐Gil, Manuel, Upton, Laura, Berenbaum, Francis, Bhana, Suleman, Costello, Wendy, Hausmann, Jonathan, Machado, Pedro, Robinson, Philip, Sirotich, Emily, Sufka, Paul, Yazdany, Jinoos, Liew, Jean, Grainger, Rebecca, Wallace, Zachary, Jayatilleke, Arundathi, and Alliance, The Global Rheumatology

Subjects
Health Services, Clinical Research, Networking and Information Technology R&D (NITRD), Good Health and Well Being, Global Rheumatology Alliance
Abstract

ObjectiveTo evaluate the impact of telemedicine use during the coronavirus disease 2019 (COVID-19) pandemic on rheumatology trainees.MethodsA voluntary, anonymous, web-based survey was administered in English, Spanish, or French from August 19 to October 5, 2020. Adult and pediatric rheumatology trainees were invited to participate via social media and email. Using multiple-choice questions and Likert scales, the survey assessed prior and current telemedicine use, impact on training, and supervision after COVID-19 prompted rapid telemedicine implementation.ResultsSurveys were received from 302 trainees from 33 countries, with 83% in adult rheumatology training programs. Reported telemedicine use increased from 13% before the pandemic to 82% during the pandemic. United States trainees predominantly used video visits, whereas outside the United States telemedicine was predominantly audio only. Most (65%) evaluated new patients using telemedicine. More respondents were comfortable using telemedicine for follow-up patients (69%) than for new patients (25%). Only 39% of respondents reported receiving telemedicine-focused training, including instruction on software, clinical skills, and billing, whereas more than half of United States trainees (59%) had training. Postconsultation verbal discussion was the most frequent form of supervision; 24% reported no supervision. Trainees found that telemedicine negatively impacted supervision (50%) and the quality of clinical teaching received (70%), with only 9% reporting a positive impact.ConclusionsDespite widespread uptake of telemedicine, a low proportion of trainees received telemedicine training, and many lacked comfort in evaluating patients, particularly new patients. Inadequate supervision and clinical teaching were areas of concern. If telemedicine remains in widespread use, ensuring appropriate trainee supervision and teaching should be prioritized.

Published
2022

24. The impact of COVID-19 on rheumatology training—results from the COVID-19 Global Rheumatology Alliance trainee survey

Author

Young, Kristen, Yeoh, Su-Ann, Putman, Michael, Sattui, Sebastian, Conway, Richard, Graef, Elizabeth, Kilian, Adam, Konig, Maximilian, Sparks, Jeffrey, Ugarte-Gil, Manuel, Upton, Laura, Berenbaum, Francis, Bhana, Suleman, Costello, Wendy, Hausmann, Jonathan, Machado, Pedro, Robinson, Philip, Sirotich, Emily, Sufka, Paul, Yazdany, Jinoos, Liew, Jean, Grainger, Rebecca, Wallace, Zachary, and Jayatilleke, Arundathi

Subjects
Good Health and Well Being, Medical Education, COVID-19, Rheumatology Fellowship
Published
2022

25. Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study

Author

Sattui, Sebastian E, Conway, Richard, Putman, Michael S, Seet, Andrea M, Gianfrancesco, Milena A, Beins, Kaley, Hill, Catherine, Liew, David, Mackie, Sarah L, Mehta, Puja, Neill, Lorna, Gomez, Gimena, Salinas, Maria Isabel Haye, Maldonado, Federico Nicolas, Mariz, Henrique Ataide, de Sousa Studart, Samia Araujo, Araujo, Nafice Costa, Knight, Ann, Rozza, Davide, Quartuccio, Luca, Samson, Maxime, Bally, Stéphane, Maria, Alexandre TJ, Chazerain, Pascal, Hasseli, Rebecca, Müller-Ladner, Ulf, Hoyer, Bimba F, Voll, Reinhard, Torres, Rita Pinheiro, Luis, Mariana, Ribeirio, Sandra Lucia Euzebio, Al-Emadi, Samar, Sparks, Jeffrey A, Hsu, Tiffany Y-T, D’Silva, Kristin M, Patel, Naomi J, Wise, Leanna, Gilbert, Emily, Almada, Maria Valenzuela, Duarte-García, Alí, Ugarte-Gil, Manuel, Jacobsohn, Lindsay, Izadi, Zara, Strangfeld, Anja, Mateus, Elsa F, Hyrich, Kimme L, Gossec, Laure, Carmona, Loreto, Lawson-Tovey, Saskia, Kearsley-Fleet, Lianne, Schaefer, Martin, Sirotich, Emily, Hausmann, Jonathan S, Sufka, Paul, Bhana, Suleman, Liew, Jean W, Grainger, Rebecca, Machado, Pedro M, Wallace, Zachary S, Yazdany, Jinoos, Robinson, Philip C, Alliance, Global Rheumatology, Dahou, Brahim, Rath, Eva, Piette, Yves, Devinck, Mieke, Maeyaert, Bea, Ribeiro, Francinne Machado, Ribeiro, Sandra Lucia Euzebio, Pinheiro, Marcelo, Quintana, Rosana, Gómez, Gimena, Roberts, Karen, Baez, Roberto Miguel, Coello, Vanessa Castro, Salinas, María J Haye, Torres, Alvaro Andres Reyes, Alle, Gelsomina, Tanten, Romina, Ficco, Hernán Maldonado, Nieto, Romina, Gobbi, Carla, Tissera, Yohana, Pisoni, Cecilia, Paula, Alba, Albiero, Juan Alejandro, Schmid, Maria Marcela, Cosatti, Micaela, Gamba, Maria Julieta, Leandro, Carlevaris, Cusa, María Alejandra, German, Noelia, Bellomio, Veronica, Takashima, Lorena, Pera, Mariana, Cogo, Karina, Elkin, Maria Soledad Gálvez, Medina, María Alejandra, and Savio, Veronica

Subjects
Aging, Arthritis, Autoimmune Disease, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Inflammatory and immune system, Global Rheumatology Alliance
Abstract

BackgroundPatients with primary systemic vasculitis or polymyalgia rheumatica might be at a high risk for poor COVID-19 outcomes due to the treatments used, the potential organ damage cause by primary systemic vasculitis, and the demographic factors associated with these conditions. We therefore aimed to investigate factors associated with COVID-19 outcomes in patients with primary systemic vasculitis or polymyalgia rheumatica.MethodsIn this retrospective cohort study, adult patients (aged ≥18 years) diagnosed with COVID-19 between March 12, 2020, and April 12, 2021, who had a history of primary systemic vasculitis (antineutrophil cytoplasmic antibody [ANCA]-associated vasculitis, giant cell arteritis, Behçet's syndrome, or other vasculitis) or polymyalgia rheumatica, and were reported to the COVID-19 Global Rheumatology Alliance registry were included. To assess COVID-19 outcomes in patients, we used an ordinal COVID-19 severity scale, defined as: (1) no hospitalisation; (2) hospitalisation without supplemental oxygen; (3) hospitalisation with any supplemental oxygen or ventilation; or (4) death. Multivariable ordinal logistic regression analyses were used to estimate odds ratios (ORs), adjusting for age, sex, time period, number of comorbidities, smoking status, obesity, glucocorticoid use, disease activity, region, and medication category. Analyses were also stratified by type of rheumatic disease.FindingsOf 1202 eligible patients identified in the registry, 733 (61·0%) were women and 469 (39·0%) were men, and their mean age was 63·8 years (SD 17·1). A total of 374 (31·1%) patients had polymyalgia rheumatica, 353 (29·4%) had ANCA-associated vasculitis, 183 (15·2%) had giant cell arteritis, 112 (9·3%) had Behçet's syndrome, and 180 (15·0%) had other vasculitis. Of 1020 (84·9%) patients with outcome data, 512 (50·2%) were not hospitalised, 114 (11·2%) were hospitalised and did not receive supplemental oxygen, 239 (23·4%) were hospitalised and received ventilation or supplemental oxygen, and 155 (15·2%) died. A higher odds of poor COVID-19 outcomes were observed in patients who were older (per each additional decade of life OR 1·44 [95% CI 1·31-1·57]), were male compared with female (1·38 [1·05-1·80]), had more comorbidities (per each additional comorbidity 1·39 [1·23-1·58]), were taking 10 mg/day or more of prednisolone compared with none (2·14 [1·50-3·04]), or had moderate, or high or severe disease activity compared with those who had disease remission or low disease activity (2·12 [1·49-3·02]). Risk factors varied among different disease subtypes.InterpretationAmong patients with primary systemic vasculitis and polymyalgia rheumatica, severe COVID-19 outcomes were associated with variable and largely unmodifiable risk factors, such as age, sex, and number of comorbidities, as well as treatments, including high-dose glucocorticoids. Our results could be used to inform mitigation strategies for patients with these diseases.FundingAmerican College of Rheumatology and the European Alliance of Associations for Rheumatology.

Published
2021

27. Immunomodulator use, risk factors and management of flares, and mortality for patients with pre-existing rheumatoid arthritis after immune checkpoint inhibitors for cancer

Author

McCarter, Kaitlin R., Arabelovic, Senada, Wang, Xiaosong, Wolfgang, Taylor, Yoshida, Kazuki, Qian, Grace, Kowalski, Emily N., Vanni, Kathleen M.M., LeBoeuf, Nicole R., Buchbinder, Elizabeth I., Gedmintas, Lydia, MacFarlane, Lindsey A., Rao, Deepak A., Shadick, Nancy A., Gravallese, Ellen M., and Sparks, Jeffrey A.

Published
2024
Full Text
View/download PDF

31. Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases

Author

Hausmann, Jonathan S, Kennedy, Kevin, Simard, Julia F, Liew, Jean W, Sparks, Jeffrey A, Moni, Tarin T, Harrison, Carly, Larché, Maggie J, Levine, Mitchell, Sattui, Sebastian E, Semalulu, Teresa, Foster, Gary, Surangiwala, Salman, Thabane, Lehana, Beesley, Richard P, Durrant, Karen L, Mateus, Elsa F, Mingolla, Serena, Nudel, Michal, Palmerlee, Candace A, Richards, Dawn P, Liew, David FL, Hill, Catherine L, Bhana, Suleman, Costello, Wendy, Grainger, Rebecca, Machado, Pedro M, Robinson, Philip C, Sufka, Paul, Wallace, Zachary S, Yazdany, Jinoos, Sirotich, Emily, Alliance, COVID-19 Global Rheumatology, Sufka, Paul H, Singh, Namrata, Howard, Richard A, Kim, Alfred HJ, Westrich-Robertson, Tiffany, Tsui, Edmund, Duarte-Garcia, Ali, Tam, Herman, Jayatilleke, Arundathi, Konig, Maximilian F, Graef, Elizabeth R, Putman, Michael S, Syed, Reema H, Korsten, Peter, Mateus, Elsa, Laura, Upton A, Adam, Kilian, Chock, Yu Pei Eugenia, White, Douglas W, Zamora, Geraldine T, Traboco, Lisa S, Patel, Aarat M, Ugarte-Gil, Manuel F, Gianfrancesco, Milena A, Amigues, Isabelle, Sanchez-Alvarez, Catalina, Trupin, Laura, Jacobsohn, Lindsay R, Hoyer, Bimba F, Makan, Kavita, Gossec, Laure, Priyank, Chaudhary, Leipe, Jan, Wallace, Beth, Angeles-Han, Sheila T, Almaghlouth, Ibrahim A, Katherine, Wysham D, Padula, Anthony S, Berenbaum, Francis, Treemarcki, Erin M, Sinha, Rashmi, Lewandowski, Laura B, Webb, Kate, Young, Kristen J, Bulina, Inita, Uribe, Sebastian Herrera, Rubinstein, Tamar B, Nolan, Marc W, Ang, Elizabeth Y, Venuturupalli, Swamy R, Dubreuil, Maureen, Pisoni, Cecilia N, Cosatti, Micaela A, Campos, Jose, and Conway, Richard

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Arthritis, Autoimmune Disease, Coronaviruses, Infectious Diseases, Emerging Infectious Diseases, Aging, Coronaviruses Disparities and At-Risk Populations, Women's Health, 7.1 Individual care needs, Generic health relevance, Inflammatory and immune system, Good Health and Well Being, COVID-19 Global Rheumatology Alliance, Clinical sciences
Abstract

BackgroundThe impact and consequences of the COVID-19 pandemic on people with rheumatic disease are unclear. We developed the COVID-19 Global Rheumatology Alliance Patient Experience Survey to assess the effects of the COVID-19 pandemic on people with rheumatic disease worldwide.MethodsSurvey questions were developed by key stakeholder groups and disseminated worldwide through social media, websites, and patient support organisations. Questions included demographics, rheumatic disease diagnosis, COVID-19 diagnosis, adoption of protective behaviours to mitigate COVID-19 exposure, medication access and changes, health-care access and communication with rheumatologists, and changes in employment or schooling. Adults age 18 years and older with inflammatory or autoimmune rheumatic diseases were eligible for inclusion. We included participants with and without a COVID-19 diagnosis. We excluded participants reporting only non-inflammatory rheumatic diseases such as fibromyalgia or osteoarthritis.Findings12 117 responses to the survey were received between April 3 and May 8, 2020, and of these, 10 407 respondents had included appropriate age data. We included complete responses from 9300 adults with rheumatic disease (mean age 46·1 years; 8375 [90·1%] women, 893 [9·6%] men, and 32 [0·3%] participants who identified as non-binary). 6273 (67·5%) of respondents identified as White, 1565 (16·8%) as Latin American, 198 (2·1%) as Black, 190 (2·0%) as Asian, and 42 (0·5%) as Native American or Aboriginal or First Nation. The most common rheumatic disease diagnoses included rheumatoid arthritis (3636 [39·1%] of 9300), systemic lupus erythematosus (2882 [31·0%]), and Sjögren's syndrome (1290 [13·9%]). Most respondents (6921 [82·0%] of 8441) continued their antirheumatic medications as prescribed. Almost all (9266 [99·7%] of 9297) respondents adopted protective behaviours to limit SARS-CoV-2 exposure. A change in employment status occurred in 2524 (27·1%) of 9300) of respondents, with a 13·6% decrease in the number in full-time employment (from 4066 to 3514).InterpretationPeople with rheumatic disease maintained therapy and followed public health advice to mitigate the risks of COVID-19. Substantial employment status changes occurred, with potential implications for health-care access, medication affordability, mental health, and rheumatic disease activity.FundingAmerican College of Rheumatology.

Published
2021

32. Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey

Author

Sattui, Sebastian Eduardo, Liew, Jean W, Kennedy, Kevin, Sirotich, Emily, Putman, Michael, Moni, Tarin T, Akpabio, Akpabio, Alpízar-Rodríguez, Deshiré, Berenbaum, Francis, Bulina, Inita, Conway, Richard, Singh, Aman Dev, Duff, Eimear, Durrant, Karen L, Gheita, Tamer A, Hill, Catherine L, Howard, Richard A, Hoyer, Bimba F, Hsieh, Evelyn, Kibbi, Lina El, Kilian, Adam, Kim, Alfred Hyoungju, Liew, David FL, Lo, Chieh, Miller, Bruce, Mingolla, Serena, Nudel, Michal, Palmerlee, Candace A, Singh, Jasvinder A, Singh, Namrata, Ugarte-Gil, Manuel Francisco, Wallace, John, Young, Kristen J, Bhana, Suleman, Costello, Wendy, Grainger, Rebecca, Machado, Pedro M, Robinson, Philip C, Sufka, Paul, Wallace, Zachary S, Yazdany, Jinoos, Harrison, Carly, Larché, Maggie, Levine, Mitchell, Foster, Gary, Thabane, Lehana, Rider, Lisa G, Hausmann, Jonathan S, Simard, Julia F, and Sparks, Jeffrey A

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Prevention, Arthritis, Infectious Diseases, Autoimmune Disease, Vaccine Related, Emerging Infectious Diseases, Coronaviruses Vaccines, Patient Safety, Women's Health, Coronaviruses, Aging, Immunization, 6.1 Pharmaceuticals, 3.4 Vaccines, Inflammatory and immune system, Good Health and Well Being, Adult, COVID-19, COVID-19 Vaccines, Female, Humans, Male, Middle Aged, Rheumatic Diseases, Rheumatology, SARS-CoV-2, Surveys and Questionnaires, Vaccination, vaccination, autoimmune diseases, Clinical sciences
Abstract

BackgroundWe describe the early experiences of adults with systemic rheumatic disease who received the COVID-19 vaccine.MethodsFrom 2 April to 30 April 2021, we conducted an online, international survey of adults with systemic rheumatic disease who received COVID-19 vaccination. We collected patient-reported data on clinician communication, beliefs and intent about discontinuing disease-modifying antirheumatic drugs (DMARDs) around the time of vaccination, and patient-reported adverse events after vaccination.ResultsWe analysed 2860 adults with systemic rheumatic diseases who received COVID-19 vaccination (mean age 55.3 years, 86.7% female, 86.3% white). Types of COVID-19 vaccines were Pfizer-BioNTech (53.2%), Oxford/AstraZeneca (22.6%), Moderna (21.3%), Janssen/Johnson & Johnson (1.7%) and others (1.2%). The most common rheumatic disease was rheumatoid arthritis (42.3%), and 81.2% of respondents were on a DMARD. The majority (81.9%) reported communicating with clinicians about vaccination. Most (66.9%) were willing to temporarily discontinue DMARDs to improve vaccine efficacy, although many (44.3%) were concerned about rheumatic disease flares. After vaccination, the most reported patient-reported adverse events were fatigue/somnolence (33.4%), headache (27.7%), muscle/joint pains (22.8%) and fever/chills (19.9%). Rheumatic disease flares that required medication changes occurred in 4.6%.ConclusionAmong adults with systemic rheumatic disease who received COVID-19 vaccination, patient-reported adverse events were typical of those reported in the general population. Most patients were willing to temporarily discontinue DMARDs to improve vaccine efficacy. The relatively low frequency of rheumatic disease flare requiring medications was reassuring.

Published
2021

33. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry

Author

Sparks, Jeffrey A, Wallace, Zachary S, Seet, Andrea M, Gianfrancesco, Milena A, Izadi, Zara, Hyrich, Kimme L, Strangfeld, Anja, Gossec, Laure, Carmona, Loreto, Mateus, Elsa F, Lawson-Tovey, Saskia, Trupin, Laura, Rush, Stephanie, Katz, Patricia, Schmajuk, Gabriela, Jacobsohn, Lindsay, Wise, Leanna, Gilbert, Emily L, Duarte-García, Ali, Valenzuela-Almada, Maria O, Pons-Estel, Guillermo J, Isnardi, Carolina A, Berbotto, Guillermo A, Hsu, Tiffany Y-T, D’Silva, Kristin M, Patel, Naomi J, Kearsley-Fleet, Lianne, Schäfer, Martin, Ribeiro, Sandra Lúcia Euzébio, Al Emadi, Samar, Tidblad, Liselotte, Scirè, Carlo Alberto, Raffeiner, Bernd, Thomas, Thierry, Flipo, René-Marc, Avouac, Jérôme, Seror, Raphaèle, Bernardes, Miguel, Cunha, Maria Margarida, Hasseli, Rebecca, Schulze-Koops, Hendrik, Müller-Ladner, Ulf, Specker, Christof, de Souza, Viviane Angelina, da Mota, Licia Maria Henrique, Gomides, Ana Paula Monteiro, Dieudé, Philippe, Nikiphorou, Elena, Kronzer, Vanessa L, Singh, Namrata, Ugarte-Gil, Manuel F, Wallace, Beth, Akpabio, Akpabio, Thomas, Ranjeny, Bhana, Suleman, Costello, Wendy, Grainger, Rebecca, Hausmann, Jonathan S, Liew, Jean W, Sirotich, Emily, Sufka, Paul, Robinson, Philip C, Machado, Pedro M, Yazdany, Jinoos, Dahou, Brahim, Quintana, Rosana, Gómez, Gimena, Roberts, Karen, Baez, Roberto Miguel, Coello, Vanessa Castro, Salinas, María Haye, Maldonado, Federico Nicolas, Reyes, Alvaro Andres, Alle, Gelsomina, Tanten, Romina, Ficco, Hernán Maldonado, Nieto, Romina, Gobbi, Carla, Tissera, Yohana, Pisoni, Cecilia, Paula, Alba, Albiero, Juan Alejandro, Schmid, Maria Marcela, Cosatti, Micaela, Gamba, Maria Julieta, Leandro, Carlevaris, Cusa, María Alejandra, German, Noelia, Bellomio, Veronica, Takashima, Lorena, Pera, Mariana, Cogo, Karina, Elkin, Maria Soledad, Medina, María Alejandra, Savio, Veronica, Tessel, Ivana Romina, Alamino, Rodolfo Perez, Werner, Marina Laura, Ornella, Sofía, and Casalla, Luciana

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Rheumatoid Arthritis, Infectious Diseases, Arthritis, Coronaviruses, Emerging Infectious Diseases, Autoimmune Disease, 6.1 Pharmaceuticals, Inflammatory and immune system, Good Health and Well Being, Aged, Antirheumatic Agents, Arthritis, Rheumatoid, COVID-19, Female, Humans, Male, Middle Aged, Registries, SARS-CoV-2, Severity of Illness Index, COVID-19 Global Rheumatology Alliance, Covid-19, abatacept, rheumatoid arthritis, rituximab, tumour necrosis factor inhibitors, Immunology, Public Health and Health Services, Arthritis & Rheumatology, Clinical sciences
Abstract

ObjectiveTo investigate baseline use of biologic or targeted synthetic (b/ts) disease-modifying antirheumatic drugs (DMARDs) and COVID-19 outcomes in rheumatoid arthritis (RA).MethodsWe analysed the COVID-19 Global Rheumatology Alliance physician registry (from 24 March 2020 to 12 April 2021). We investigated b/tsDMARD use for RA at the clinical onset of COVID-19 (baseline): abatacept (ABA), rituximab (RTX), Janus kinase inhibitors (JAKi), interleukin 6 inhibitors (IL-6i) or tumour necrosis factor inhibitors (TNFi, reference group). The ordinal COVID-19 severity outcome was (1) no hospitalisation, (2) hospitalisation without oxygen, (3) hospitalisation with oxygen/ventilation or (4) death. We used ordinal logistic regression to estimate the OR (odds of being one level higher on the ordinal outcome) for each drug class compared with TNFi, adjusting for potential baseline confounders.ResultsOf 2869 people with RA (mean age 56.7 years, 80.8% female) on b/tsDMARD at the onset of COVID-19, there were 237 on ABA, 364 on RTX, 317 on IL-6i, 563 on JAKi and 1388 on TNFi. Overall, 613 (21%) were hospitalised and 157 (5.5%) died. RTX (OR 4.15, 95% CI 3.16 to 5.44) and JAKi (OR 2.06, 95% CI 1.60 to 2.65) were each associated with worse COVID-19 severity compared with TNFi. There were no associations between ABA or IL6i and COVID-19 severity.ConclusionsPeople with RA treated with RTX or JAKi had worse COVID-19 severity than those on TNFi. The strong association of RTX and JAKi use with poor COVID-19 outcomes highlights prioritisation of risk mitigation strategies for these people.

Published
2021

34. Sarcoidosis

Author

Judson, Marc A., Lower, Elyse E., Chen, Edward S., Sparks, Jeffrey A., Farmer, Jocelyn R., Baughman, Robert P., and Stone, John H., editor

Published
2023
Full Text
View/download PDF

35. Effectiveness of a fourth dose of COVID-19 mRNA vaccine in patients with systemic autoimmune rheumatic diseases using disease-modifying antirheumatic drugs: an emulated target trial

Author

Hanberg, Jennifer S, Fu, Xiaoqing, Wang, Xiaosong, Patel, Naomi J, Kawano, Yumeko, Schiff, Abigail, Kowalski, Emily N, Cook, Claire E, Vanni, Kathleen M M, Guzzo, Krishan, Qian, Grace, Bade, Katarina J, Saavedra, Alene, Venkat, Rathnam, Srivatsan, Shruthi, Zhang, Yuqing, Sparks, Jeffrey A, and Wallace, Zachary S

Published
2024
Full Text
View/download PDF

36. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry

Author

Strangfeld, Anja, Schäfer, Martin, Gianfrancesco, Milena A, Lawson-Tovey, Saskia, Liew, Jean W, Ljung, Lotta, Mateus, Elsa F, Richez, Christophe, Santos, Maria J, Schmajuk, Gabriela, Scirè, Carlo A, Sirotich, Emily, Sparks, Jeffrey A, Sufka, Paul, Thomas, Thierry, Trupin, Laura, Wallace, Zachary S, Al-Adely, Sarah, Bachiller-Corral, Javier, Bhana, Suleman, Cacoub, Patrice, Carmona, Loreto, Costello, Ruth, Costello, Wendy, Gossec, Laure, Grainger, Rebecca, Hachulla, Eric, Hasseli, Rebecca, Hausmann, Jonathan S, Hyrich, Kimme L, Izadi, Zara, Jacobsohn, Lindsay, Katz, Patricia, Kearsley-Fleet, Lianne, Robinson, Philip C, Yazdany, Jinoos, Machado, Pedro M, Dahou, Brahim, Pinheiro, Marcelo, Ribeiro, Francinne M, Chassin-Trubert, Anne-Marie, Ibáñez, Sebastián, Dong, Lingli, Cajas, Lui, Hamoud, Hesham, Avouac, Jérôme, Belin, Véronique, Borie, Raphaël, Chazerain, Pascal, Chevalier, Xavier, Claudepierre, Pascal, Clavel, Gaëlle, Colette-Cedoz, Marie-Eve, Combe, Bernard, Constant, Elodie, Costedoat-Chalumeau, Nathalie, Desmurs, Marie, Devauchelle-Pensec, Valérie, Devaux, Mathilde, Dhote, Robin, Dieudonné, Yannick, Domont, Fanny, Duret, Pierre-Marie, Ebbo, Mikaël, Ebstein, Esther, Mahou, Soumaya El, Fautrel, Bruno, Felten, Renaud, Flipo, René-Marc, Foltz, Violaine, Froissart, Antoine, Galland, Joris, Gaud-Listrat, Véronique, Georgin-Lavialle, Sophie, Giraud-Morelet, Aude, Quitrec, Jeanine S Giraudet-Le, Goupille, Philippe, Govindaraju-Audouard, Sophie, Grados, Franck, Guillaume-Czitrom, Séverine, Hermet, Marion, Hittinger-Roux, Ambre, Hudry, Christophe, Kone-Paut, Isabelle, La Batide Alanore, Sylvain, Lafforgue, Pierre, Lahalle, Sophie, Lambrecht, Isabelle, Langlois, Vincent, Larbre, Jean-Paul, Ledoult, Emmanuel, Leroux, Christophe, Liote, Frédéric, Maria, Alexandre TJ, Marotte, Hubert, Mekinian, Arsène, Melki, Isabelle, Messer, Laurent, Michel, Catherine, and Morel, Gauthier

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Arthritis, Autoimmune Disease, Emerging Infectious Diseases, Infectious Diseases, Coronaviruses, Inflammatory and immune system, Cardiovascular, Good Health and Well Being, Aged, Antirheumatic Agents, COVID-19, Comorbidity, Female, Global Health, Glucocorticoids, Humans, Male, Middle Aged, Odds Ratio, Registries, Rheumatic Diseases, Rheumatology, SARS-CoV-2, antirheumatic agents, autoimmune diseases, epidemiology, glucocorticoids, outcome assessment, health care, COVID-19 Global Rheumatology Alliance, Immunology, Public Health and Health Services, Arthritis & Rheumatology, Clinical sciences
Abstract

ObjectivesTo determine factors associated with COVID-19-related death in people with rheumatic diseases.MethodsPhysician-reported registry of adults with rheumatic disease and confirmed or presumptive COVID-19 (from 24 March to 1 July 2020). The primary outcome was COVID-19-related death. Age, sex, smoking status, comorbidities, rheumatic disease diagnosis, disease activity and medications were included as covariates in multivariable logistic regression models. Analyses were further stratified according to rheumatic disease category.ResultsOf 3729 patients (mean age 57 years, 68% female), 390 (10.5%) died. Independent factors associated with COVID-19-related death were age (66-75 years: OR 3.00, 95% CI 2.13 to 4.22; >75 years: 6.18, 4.47 to 8.53; both vs ≤65 years), male sex (1.46, 1.11 to 1.91), hypertension combined with cardiovascular disease (1.89, 1.31 to 2.73), chronic lung disease (1.68, 1.26 to 2.25) and prednisolone-equivalent dosage >10 mg/day (1.69, 1.18 to 2.41; vs no glucocorticoid intake). Moderate/high disease activity (vs remission/low disease activity) was associated with higher odds of death (1.87, 1.27 to 2.77). Rituximab (4.04, 2.32 to 7.03), sulfasalazine (3.60, 1.66 to 7.78), immunosuppressants (azathioprine, cyclophosphamide, ciclosporin, mycophenolate or tacrolimus: 2.22, 1.43 to 3.46) and not receiving any disease-modifying anti-rheumatic drug (DMARD) (2.11, 1.48 to 3.01) were associated with higher odds of death, compared with methotrexate monotherapy. Other synthetic/biological DMARDs were not associated with COVID-19-related death.ConclusionAmong people with rheumatic disease, COVID-19-related death was associated with known general factors (older age, male sex and specific comorbidities) and disease-specific factors (disease activity and specific medications). The association with moderate/high disease activity highlights the importance of adequate disease control with DMARDs, preferably without increasing glucocorticoid dosages. Caution may be required with rituximab, sulfasalazine and some immunosuppressants.

Published
2021

37. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

Author

Fraenkel, Liana, Bathon, Joan M, England, Bryant R, St.Clair, E William, Arayssi, Thurayya, Carandang, Kristine, Deane, Kevin D, Genovese, Mark, Huston, Kent Kwas, Kerr, Gail, Kremer, Joel, Nakamura, Mary C, Russell, Linda A, Singh, Jasvinder A, Smith, Benjamin J, Sparks, Jeffrey A, Venkatachalam, Shilpa, Weinblatt, Michael E, Al‐Gibbawi, Mounir, Baker, Joshua F, Barbour, Kamil E, Barton, Jennifer L, Cappelli, Laura, Chamseddine, Fatimah, George, Michael, Johnson, Sindhu R, Kahale, Lara, Karam, Basil S, Khamis, Assem M, Navarro-Millán, Iris, Mirza, Reza, Schwab, Pascale, Singh, Namrata, Turgunbaev, Marat, Turner, Amy S, Yaacoub, Sally, and Akl, Elie A

Subjects
Arthritis, Clinical Research, Management of diseases and conditions, 7.3 Management and decision making, Inflammatory and immune system, Good Health and Well Being, Antirheumatic Agents, Arthritis, Rheumatoid, Clinical Decision-Making, Consensus, Decision Support Techniques, Humans, Remission Induction, Rheumatology, Treatment Outcome, Clinical Sciences, Public Health and Health Services, Psychology
Abstract

ObjectiveTo develop updated guidelines for the pharmacologic management of rheumatoid arthritis.MethodsWe developed clinically relevant population, intervention, comparator, and outcomes (PICO) questions. After conducting a systematic literature review, the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to rate the certainty of evidence. A voting panel comprising clinicians and patients achieved consensus on the direction (for or against) and strength (strong or conditional) of recommendations.ResultsThe guideline addresses treatment with disease-modifying antirheumatic drugs (DMARDs), including conventional synthetic DMARDs, biologic DMARDs, and targeted synthetic DMARDs, use of glucocorticoids, and use of DMARDs in certain high-risk populations (i.e., those with liver disease, heart failure, lymphoproliferative disorders, previous serious infections, and nontuberculous mycobacterial lung disease). The guideline includes 44 recommendations (7 strong and 37 conditional).ConclusionThis clinical practice guideline is intended to serve as a tool to support clinician and patient decision-making. Recommendations are not prescriptive, and individual treatment decisions should be made through a shared decision-making process based on patients' values, goals, preferences, and comorbidities.

Published
2021

38. Impact of Risk Factors on COVID‐19 Outcomes in Unvaccinated People With Rheumatic Diseases: A Comparative Analysis of Pandemic Epochs Using the COVID‐19 Global Rheumatology Alliance Registry

Author

Yazdany, Jinoos, Ware, Anna, Wallace, Zachary S., Bhana, Suleman, Grainger, Rebecca, Hachulla, Eric, Richez, Christophe, Cacoub, Patrice, Hausmann, Jonathan S., Liew, Jean W., Sirotich, Emily, Jacobsohn, Lindsay, Strangfeld, Anja, Mateus, Elsa F., Hyrich, Kimme L., Gossec, Laure, Carmona, Loreto, Lawson‐Tovey, Saskia, Kearsley‐Fleet, Lianne, Schaefer, Martin, Ribeiro, Sandra Lucia Euzebio, Al‐Emadi, Samar, Hasseli, Rebecca, Müller‐Ladner, Ulf, Specker, Christof, Schulze‐Koops, Hendrik, Bernardes, Miguel, Fraga, Vanessa Machado, Rodrigues, Ana Maria, Sparks, Jeffrey A., Ljung, Lotta, Di Giuseppe, Daniela, Tidblad, Liselotte, Wise, Leanna, Duarte‐García, Alí, Ugarte‐Gil, Manuel F., Colunga‐Pedraza, Iris Jazmín, Martínez‐Martínez, Marco Ulises, Alpizar‐Rodriguez, Deshire, Xavier, Ricardo Machado, Isnardi, Carolina A., Pera, Mariana, Pons‐Estel, Guillermo, Izadi, Zara, Gianfrancesco, Milena A., Carrara, Greta, Scirè, Carlo Alberto, Zanetti, Anna, and Machado, Pedro M.

Published
2024
Full Text
View/download PDF

39. Polygenic risk scores identify heterogeneity in asthma and chronic obstructive pulmonary disease

Author

Moll, Matthew, Sordillo, Joanne E., Ghosh, Auyon J., Hayden, Lystra P., McDermott, Gregory, McGeachie, Michael J., Dahlin, Amber, Tiwari, Anshul, Manmadkar, Monica G., Abston, Eric D., Pavuluri, Chandan, Saferali, Aabida, Begum, Sofina, Ziniti, John P., Gulsvik, Amund, Bakke, Per S., Aschard, Hugues, Iribarren, Carlos, Hersh, Craig P., Sparks, Jeffrey A., Hobbs, Brian D., Lasky-Su, Jessica A., Silverman, Edwin K., Weiss, Scott T., Wu, Ann Chen, and Cho, Michael H.

Published
2023
Full Text
View/download PDF

42. Identification of a regulatory pathway governing TRAF1 via an arthritis-associated non-coding variant

Author

Wang, Qiang, Martínez-Bonet, Marta, Kim, Taehyeung, Sparks, Jeffrey A., Ishigaki, Kazuyoshi, Chen, Xiaoting, Sudman, Marc, Aguiar, Vitor, Sim, Sangwan, Hernandez, Marcos Chiñas, Chiu, Darren J., Wactor, Alexandra, Wauford, Brian, Marion, Miranda C., Gutierrez-Arcelus, Maria, Bowes, John, Eyre, Stephen, Nordal, Ellen, Prahalad, Sampath, Rygg, Marite, Videm, Vibeke, Raychaudhuri, Soumya, Weirauch, Matthew T., Langefeld, Carl D., Thompson, Susan D., and Nigrovic, Peter A.

Published
2023
Full Text
View/download PDF

43. Association of Race and Ethnicity With COVID‐19 Outcomes in Rheumatic Disease: Data From the COVID‐19 Global Rheumatology Alliance Physician Registry

Author

Gianfrancesco, Milena A, Leykina, Liza A, Izadi, Zara, Taylor, Tiffany, Sparks, Jeffrey A, Harrison, Carly, Trupin, Laura, Rush, Stephanie, Schmajuk, Gabriela, Katz, Patricia, Jacobsohn, Lindsay, Hsu, Tiffany Y, D’Silva, Kristin M, Serling‐Boyd, Naomi, Wallwork, Rachel, Todd, Derrick J, Bhana, Suleman, Costello, Wendy, Grainger, Rebecca, Hausmann, Jonathan S, Liew, Jean W, Sirotich, Emily, Sufka, Paul, Wallace, Zachary S, Machado, Pedro M, Robinson, Philip C, Yazdany, Jinoos, and Alliance, the COVID‐19 Global Rheumatology

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Health Disparities, Minority Health, Arthritis, Clinical Research, Emerging Infectious Diseases, Coronaviruses, Social Determinants of Health, Infectious Diseases, Good Health and Well Being, Adolescent, Adult, Aged, COVID-19, Cross-Sectional Studies, Ethnicity, Female, Hospitalization, Humans, Male, Middle Aged, Odds Ratio, Racial Groups, Registries, Respiration, Artificial, Rheumatic Diseases, Rheumatology, SARS-CoV-2, United States, Young Adult, COVID-19 Global Rheumatology Alliance
Abstract

ObjectiveRacial/ethnic minorities experience more severe outcomes of coronavirus disease 2019 (COVID-19) in the general US population. This study was undertaken to examine the association between race/ethnicity and COVID-19 hospitalization, ventilation status, and mortality in people with rheumatic disease.MethodsUS patients with rheumatic disease and COVID-19 were entered into the COVID-19 Global Rheumatology Alliance physician registry between March 24, 2020 and August 26, 2020 were included. Race/ethnicity was defined as White, African American, Latinx, Asian, or other/mixed race. Outcome measures included hospitalization, requirement for ventilatory support, and death. Multivariable regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (95% CIs) adjusted for age, sex, smoking status, rheumatic disease diagnosis, comorbidities, medication use prior to infection, and rheumatic disease activity.ResultsA total of 1,324 patients were included, of whom 36% were hospitalized and 6% died; 26% of hospitalized patients required mechanical ventilation. In multivariable models, African American patients (OR 2.74 [95% CI 1.90-3.95]), Latinx patients (OR 1.71 [95% CI 1.18-2.49]), and Asian patients (OR 2.69 [95% CI 1.16-6.24]) had higher odds of hospitalization compared to White patients. Latinx patients also had 3-fold increased odds of requiring ventilatory support (OR 3.25 [95% CI 1.75-6.05]). No differences in mortality based on race/ethnicity were found, though power to detect associations may have been limited.ConclusionSimilar to findings in the general US population, racial/ethnic minorities with rheumatic disease and COVID-19 had increased odds of hospitalization and ventilatory support. These results illustrate significant health disparities related to COVID-19 in people with rheumatic diseases. The rheumatology community should proactively address the needs of patients currently experiencing inequitable health outcomes during the pandemic.

Published
2021

45. Mortality and immune-related adverse events after immune checkpoint inhibitor initiation for cancer among patients with pre-existing rheumatoid arthritis: a retrospective, comparative, cohort study

Author

McCarter, Kaitlin R, Wolfgang, Taylor, Arabelovic, Senada, Wang, Xiaosong, Yoshida, Kazuki, Banasiak, Emily P, Qian, Grace, Kowalski, Emily N, Vanni, Kathleen M M, LeBoeuf, Nicole R, Buchbinder, Elizabeth I, Gedmintas, Lydia, MacFarlane, Lindsey A, Rao, Deepak A, Shadick, Nancy A, Gravallese, Ellen M, and Sparks, Jeffrey A

Published
2023
Full Text
View/download PDF

46. Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study

Author

Dahou, Brahim, Rath, Eva, Piette, Yves, Devinck, Mieke, Maeyaert, Bea, Machado Ribeiro, Francinne, Euzebio Ribeiro, Sandra Lucia, Pinheiro, Marcelo, Quintana, Rosana, Gómez, Gimena, Roberts, Karen, Baez, Roberto Miguel, Castro Coello, Vanessa, Haye Salinas, María J., Maldonado, Federico Nicolas, Reyes Torres, Alvaro Andres, Alle, Gelsomina, Tanten, Romina, Maldonado Ficco, Hernán, Nieto, Romina, Gobbi, Carla, Tissera, Yohana, Pisoni, Cecilia, Paula, Alba, Albiero, Juan Alejandro, Schmid, Maria Marcela, Cosatti, Micaela, Gamba, Maria Julieta, Leandro, Carlevaris, Cusa, María Alejandra, German, Noelia, Bellomio, Veronica, Takashima, Lorena, Pera, Mariana, Cogo, Karina, Gálvez Elkin, Maria Soledad, Medina, María Alejandra, Savio, Veronica, Rojas Tessel, Ivana Romina, Perez Alamino, Rodolfo, Werner, Marina Laura, Ornella, Sofía, Casalla, Luciana, de la Vega, Maria, Severina, María, García, Mercedes, Gonzalez Lucero, Luciana, Romeo, Cecilia, Moyano, Sebastián, Barbich, Tatiana, Bertoli, Ana, Baños, Andrea, Petruzzelli, Sandra, Matellan, Carla, Conti, Silvana, Lazaro, Ma. Alicia, Rodriguez Gil, Gustavo Fabián, Risueño, Fabian, Quaglia, Maria Isabel, Scafati, Julia, Cuchiaro, Natalia Lili, Rebak, Jonathan Eliseo, Pineda, Susana Isabel, Calvo, María Elena, Picco, Eugenia, Gallino Yanzi, Josefina, Maid, Pablo, Guaglianone, Debora, Morbiducci, Julieta Silvana, Porta, Sabrina, Herscovich, Natalia, Velasco Zamora, José Luis, Kisluk, Boris, Castaños Menescardi, Maria Sol, Gallo, Rosana, Martire, María Victoria, Maldini, Carla, Goizueta, Cecilia, de la Vega Fernandez, Sabrina Solange, Aeschlimann, Carolina, Subils, Gisela, Ibáñez, Sebastián, Chassin-Trubert, Anne-Marie, Dong, Lingli, Cajas, Lui, Barešic, Marko, Anic, Branimir, Culo, Melanie-Ivana, Pavelic, Tea Ahel, Kovacevic Stranski, Kristina, Karanovic, Boris, Vencovsky, Jiri, Píchová, Marta, Filkova, Maria, Hamoud, Hesham, Vassilopoulos, Dimitrios, Guzman Melgar, Gabriela Maria, So, Ho, Király, Márta, Vojdanian, Mahdi, Balbir-Gurman, Alexandra, Abutiban, Fatemah, Zepa, Julija, Bulina, Inita, Bukauskiene, Loreta, Zaueta, Beatriz, Castillo Ortiz, Angel Alejandro, Zamora Tehozol, Erick, Vega, David, Cervántes Rosete, Diana, Martín Nares, Eduardo, Rodriguez-Reyna, Tatiana Sofia, Rull Gabayet, Marina, Alpízar-Rodríguez, Deshiré, Irazoque, Fedra, Jimenez, Xochitl, Geurts-van Bon, Lenny, Zijlstra, Theo, Hoekstra, Monique, Al-Adhoubi, Nasra, Salim, Babur, Giraldo, Enrique, Salinas, Ariel, Ugarte-Gil, Manuel, Nowakowski, Jaroslaw, Al-Emadi, Samar, Conway, Richard, Flood, Rachael, McCarthy, Geraldine, Felea, Ioana, Filipescu, Ileana, Rednic, Simona, Groseanu, Laura, Tamas, Maria Magdelena, Mlynarikova, Vanda, Skamlova, Martina, Zlnay, Martin, Miceková, Dagmar, Capova, Lubica, Macejova, Zelmira, Štenová, Emoke, Raffayova, Helena, Belakova, Gabriela, Strakova, Eva, Sencarová, Marieta, Žlnayová, Sona, Anna Sabová, Anna, Spisakova, Daniela, Oetterová, Mária, Lukacova, Olga, Bakosova, Martina, Hocevar, Alojzija, de la Torre-Rubio, Natalia, Alegre Sancho, Juan José, Corteguera Coro, Montserrat, Cobeta Garcia, Juan Carlos, Torres Martin, Maria Carmen, Campos, Jose, Gomez Puerta, Jose A, Yardimci, Gozd Kubra, Akar, Servet, Icacan, Ozan Cemal, Çelik, Selda, Vasylets, Viktoriia, Yeoh, Su-Ann, Vandevelde, Claire, Dunt, Sasha, Leeder, Jane, Macphie, Elizabeth, Salerno, Rosaria, Graver, Christine, Williams, Katie, O'Reilly, Sheila, Devine, Kirsty, Tyler, Jennifer, Warner, Elizabeth, Pilcher, James, Patel, Samir, Nikiphorou, Elena, Chadwick, Laura, Jones, Caroline Mulvaney, Harrison, Beverley, Thornton, Lucy, O'Kane, Diana, Fusi, Lucia, Low, Audrey, Horton, Sarah, Jatwani, Shraddha, Baig, Sara, Bajwa, Hammad, Berglund, Vernon, Dahle, Angela, Dorman, Walter, Hargrove, Jody, Hilton, Maren, Lebedoff, Nicholas, Leonard, Susan, Morgan, Jennifer, Pfeifer, Emily, Skemp, Archibald, Wilson, Jeffrey, Wolff, Anne, Cepeda, Eduardo, D'Silva, Kristin, Hsu, Tiffany, Patel, Naomi, Sparks, Jeffrey, Todd, Derrick, Wallace, Zachary, Hare, Denise, Calabrese, Cassandra, Adams, Christopher, Khosroshahi, Arezou, Kilian, Adam, White, Douglas, Winter, Melanie, Fields, Theodore, Siegel, Caroline, Daver, Nicole, Harvey, Melissa, Kramer, Neil, Lamore, Concetta, Hogarty, Suneya, Yeter, Karen, Wise, Leanna, Siddique, Faizah, Ban, Byung, Tanner, Tamar, Ruderman, Eric, Davis, William, Quinet, Robert, Scopelitis, Evangeline, Toribio Toribio, Karen, Webb-Detiege, Tameka, Zakem, Jerald, Abbass, Khurram, Kepecs, Gilbert, Miranda, Lilliam, Guma, Michael, Haikal, Ammar, Mody, Sushama, Mueller, Daric, Jayatilleke, Arundathi, Zell, JoAnn, Bays, Alison, Dao, Kathryn, Fatemeh, Ezzati, Parks, Deborah, Karp, David, Quiceno, Guillermo, Sattui, Sebastian E, Putman, Michael S, Seet, Andrea M, Gianfrancesco, Milena A, Beins, Kaley, Hill, Catherine, Liew, David, Mackie, Sarah L, Mehta, Puja, Neill, Lorna, Gomez, Gimena, Salinas, Maria Isabel Haye, Mariz, Henrique Ataide, de Sousa Studart, Samia Araujo, Araujo, Nafice Costa, Knight, Ann, Rozza, Davide, Quartuccio, Luca, Samson, Maxime, Bally, Stéphane, Maria, Alexandre TJ, Chazerain, Pascal, Hasseli, Rebecca, Müller-Ladner, Ulf, Hoyer, Bimba F, Voll, Reinhard, Torres, Rita Pinheiro, Luis, Mariana, Ribeirio, Sandra Lucia Euzebio, Sparks, Jeffrey A, Hsu, Tiffany Y-T, D’Silva, Kristin M, Patel, Naomi J, Gilbert, Emily, Almada, Maria Valenzuela, Duarte-García, Alí, Jacobsohn, Lindsay, Izadi, Zara, Strangfeld, Anja, Mateus, Elsa F, Hyrich, Kimme L, Gossec, Laure, Carmona, Loreto, Lawson-Tovey, Saskia, Kearsley-Fleet, Lianne, Schaefer, Martin, Sirotich, Emily, Hausmann, Jonathan S, Sufka, Paul, Bhana, Suleman, Liew, Jean W, Grainger, Rebecca, Machado, Pedro M, Wallace, Zachary S, Yazdany, Jinoos, and Robinson, Philip C

Published
2021
Full Text
View/download PDF

47. Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases

Author

Robinson, Philip C., Bhana, Suleman, Liew, Jean W., Sufka, Paul H., Singh, Namrata, Howard, Richard A., Kim, Alfred H.J., Westrich-Robertson, Tiffany, Sirotich, Emily, Tsui, Edmund, Duarte-Garcia, Ali, Sparks, Jeffrey A., Tam, Herman, Jayatilleke, Arundathi, Konig, Maximilian F., Graef, Elizabeth R., Putman, Michael S., Syed, Reema H., Korsten, Peter, Mateus, Elsa, Sattui, Sebastian E., Wallace, Zachary S., Laura, Upton A., Adam, Kilian, Chock, Yu Pei Eugenia, White, Douglas W., Zamora, Geraldine T., Traboco, Lisa S., Patel, Aarat M., Grainger, Rebecca, Ugarte-Gil, Manuel F., Gianfrancesco, Milena A., Amigues, Isabelle, Sanchez-Alvarez, Catalina, Trupin, Laura, Jacobsohn, Lindsay R., Beesley, Richard P., Hoyer, Bimba F., Machado, Pedro M., Makan, Kavita, Gossec, Laure, Priyank, Chaudhary, Leipe, Jan, Wallace, Beth, Angeles-Han, Sheila T., Almaghlouth, Ibrahim A., Katherine, Wysham D., Padula, Anthony S., Berenbaum, Francis, Treemarcki, Erin M., Sinha, Rashmi, Lewandowski, Laura B., Webb, Kate, Young, Kristen J., Bulina, Inita, Herrera Uribe, Sebastian, Rubinstein, Tamar B., Nolan, Marc W., Ang, Elizabeth Y., Venuturupalli, Swamy R., Hausmann, Jonathan S., Dubreuil, Maureen, Pisoni, Cecilia N., Cosatti, Micaela A., Campos, Jose, Simard, Julia F., Conway, Richard, Peterson, Tiffany M., Harrison, Carly O., Felix, Christele, Richards, Dawn P., Proulx, Laurie, Akpabio, Akpabio A., Worthing, Angus B., Laidlaw, Lynn R., Reid, Pankti, Palmerlee, Candace A., Danila, Maria I., Sahar, Lotfi-Emran, Linh, Ngo Q., Agarwal, Arnav, Studenic, Paul, Liew, David F.L., Larche, Maggie J., Mingolla, Serena A.M., Zamora, Erick A., Angevare, Saskya S., Sinha, Rashmi R., Durrant, Karen L.W., Peirce, Andrea, Somers, Emily C., Cappelli, Laura C., Frankel, Brittany A., Kumar, Bharat, Silinsky Krupnikova, Sonia D., Rosario Vega, Jorge A., Frankovich, Jourdan, Fernandez-Ruiz, Ruth, Posada Velásquez, Marcela, Yeoh, Su-Ann, Marino, Maria, Nudel, Michal, Scott, Chrisiaan, Rodríguez, Cecilia, Martín Mancheño, Ana I., Seo, Philip, Gamboa-Cárdenas, Rocío V., Pimentel-Quiroz, Victor R., Reátegui-Sokolova, Cristina, Kihara, Mari, Lin, Chung M.A., Kattula, Dheera, Laila, Girgis, Carmona, Loreto, Wallace, John, Yazdany, Jinoos, Costello, Wendy, Gore-massy, Monique C., Tomasella, Laura-Ann, Kodek, Moré A., Hausmann, Jonathan S, Kennedy, Kevin, Simard, Julia F, Liew, Jean W, Sparks, Jeffrey A, Moni, Tarin T, Harrison, Carly, Larché, Maggie J, Levine, Mitchell, Sattui, Sebastian E, Semalulu, Teresa, Foster, Gary, Surangiwala, Salman, Thabane, Lehana, Beesley, Richard P, Durrant, Karen L, Mateus, Elsa F, Mingolla, Serena, Palmerlee, Candace A, Richards, Dawn P, Liew, David F L, Hill, Catherine L, Machado, Pedro M, Robinson, Philip C, Sufka, Paul, and Wallace, Zachary S

Published
2021
Full Text
View/download PDF

48. Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: a retrospective cohort study

Author

Qian, Grace, Wang, Xiaosong, Patel, Naomi J, Kawano, Yumeko, Fu, Xiaoqing, Cook, Claire E, Vanni, Kathleen M M, Kowalski, Emily N, Banasiak, Emily P, Bade, Katarina J, Srivatsan, Shruthi, Williams, Zachary K, Todd, Derrick J, Weinblatt, Michael E, Wallace, Zachary S, and Sparks, Jeffrey A

Published
2023
Full Text
View/download PDF

49. Autoantibodies against citrullinated and native proteins and prediction of rheumatoid arthritis-associated interstitial lung disease: a nested case–control study

Author

Kronzer, Vanessa L, Hayashi, Keigo, Yoshida, Kazuki, Davis, John M, III, McDermott, Gregory C, Huang, Weixing, Dellaripa, Paul F, Cui, Jing, Feathers, Vivi, Gill, Ritu R, Hatabu, Hiroto, Nishino, Mizuki, Blaustein, Rachel, Crowson, Cynthia S, Robinson, William H, Sokolove, Jeremy, Liao, Katherine P, Weinblatt, Michael E, Shadick, Nancy A, Doyle, Tracy J, and Sparks, Jeffrey A

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results